ServiceNow and Maplebear Options Trading Activity Surges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: NASDAQ.COM
- ServiceNow Options Volume: As of now, ServiceNow Inc (Ticker: NOW) has seen an options trading volume of 137,551 contracts, equivalent to approximately 13.8 million shares, representing 54.6% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Analysis: Among NOW's options, the $120 strike call option is particularly active, with 8,248 contracts traded today, representing about 824,800 underlying shares, reflecting investor expectations for future price increases.
- Maplebear Options Activity: Concurrently, Maplebear Inc (Ticker: CART) has recorded an options trading volume of 24,461 contracts, equivalent to around 2.4 million shares, which is 54.3% of its average daily trading volume over the past month, showcasing the stock's market activity.
- CART High Strike Situation: For CART, the $50 strike call option has seen a trading volume of 11,040 contracts, representing approximately 1.1 million shares, indicating optimistic sentiment among investors regarding the stock's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.030
Low
67.00
Averages
89.40
High
105.00
Current: 42.030
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ademi LLP Investigates Crinetics for Fiduciary Breaches
- Shareholder Rights Investigation: Ademi LLP is investigating Crinetics for potential breaches of fiduciary duty in its transaction with Vertex, aiming to protect shareholder rights and ensure transparency in corporate governance.
- Transaction Value Assessment: Crinetics shareholders are set to receive $85.00 per share, totaling approximately $10 billion in equity value, with a net value of $8.8 billion after estimated cash acquired, highlighting the substantial returns but raising concerns about the board's conduct.
- Anti-competitive Clauses: The transaction agreement imposes unreasonable restrictions on competing bids, penalizing Crinetics significantly if it accepts alternative offers, which could harm shareholder interests and limit market competition, prompting legal scrutiny.
- Board Accountability Review: We are examining whether Crinetics' board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest and misconduct.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Overview: Vertex Pharmaceuticals is acquiring Crinetics for $10 billion at $85 per share, reflecting strong confidence in Crinetics, with the deal expected to close in the third quarter of this year.
- Product Potential Analysis: Crinetics' Palsonify, after FDA approval, generated $10.7 million in its first full quarter, and as the only once-daily oral treatment, it has a strong market position that is expected to yield significant revenue for Vertex.
- Pipeline Prospects: Crinetics' atumelnant is in late Phase 3 trials targeting severe congenital adrenal hyperplasia, and if approved, it will address a significant unmet medical need, enhancing Vertex's product portfolio with substantial sales potential.
- Financial Strength Support: Vertex boasts over $5.5 billion in cash reserves and has secured a $4.5 billion bridge loan, ensuring that it can continue investing in new drug development post-acquisition, driving future growth and market competitiveness.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Overview: Vertex Pharmaceuticals is acquiring Crinetics for $10 billion, paying $85 per share in cash, reflecting strong confidence in Crinetics' future potential, with the deal expected to close in the third quarter of this year.
- Market Potential: Crinetics' Palsonify has received FDA approval and generated $10.7 million in revenue in its first full quarter post-launch, positioning it as the only once-daily oral treatment in the market, indicating strong commercial prospects.
- Pipeline Highlights: Crinetics' atumelnant is in late Phase 3 clinical trials targeting severe congenital adrenal hyperplasia, and if approved, it is expected to address significant unmet medical needs with multi-billion dollar sales potential.
- Strategic Investment Significance: Vertex's CEO noted that this acquisition will leverage the momentum of Palsonify and is excited about atumelnant's transformative potential in CAH treatment, potentially generating up to $5 billion in annual sales for Vertex.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Crinetics Hits Record High After Vertex's $10 Billion Acquisition
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock soared to $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with an offer of $85 per share representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and boosting market confidence in Crinetics.
- Positive Market Reaction: Crinetics shares surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Optimistic Outlook for Dominion: Dominion Energy's stock climbed to $70.59, a three-year high, benefiting from its extensive pipeline of power projects in Northern Virginia and its proposed merger with NextEra Energy, highlighting its growing role in supplying electricity to AI data centers.
- BioCryst's Strategic Shift: BioCryst Pharmaceuticals reached a new 52-week high of $11.02 as it plans to close its Birmingham research center and partner with external firms to cut costs and achieve profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Scale: Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion, with the deal expected to close in Q3 2026, marking a significant step for Vertex into a new disease area.
- Asset Value of Crinetics: Crinetics brings the drug PALSONIFY, the first approved once-daily oral therapy for adults with acromegaly, which is expected to fill a market gap; combined with other drugs, Crinetics' assets have a peak sales potential exceeding $5 billion annually.
- Financing Structure Analysis: The acquisition will be financed through a mix of cash and debt, with Vertex planning to utilize $4.5 billion in bridge financing alongside its $13 billion in cash and marketable securities, ensuring the feasibility of the acquisition without over-leveraging.
- Strategic Significance and Future Outlook: Although Vertex expects the deal to contribute to non-GAAP operating income only by 2029, this acquisition aligns with its strategy targeting serious diseases, addressing the company's diversification needs and signaling growth potential in new areas.
See More
Ademi LLP Investigates Crinetics for Fiduciary Breaches
- Shareholder Rights Investigation: Ademi LLP is investigating Crinetics for potential breaches of fiduciary duty in its transaction with Vertex, aiming to protect shareholder rights and ensure transparency in corporate governance.
- Transaction Value Assessment: Crinetics shareholders are set to receive $85.00 per share, totaling approximately $10 billion in equity value, with a net value of $8.8 billion after estimated cash acquired, highlighting the substantial returns but raising concerns about the board's conduct.
- Anti-competitive Clauses: The transaction agreement imposes unreasonable restrictions on competing bids, penalizing Crinetics significantly if it accepts alternative offers, which could harm shareholder interests and limit market competition, prompting legal scrutiny.
- Board Accountability Review: We are examining whether Crinetics' board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest and misconduct.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Overview: Vertex Pharmaceuticals is acquiring Crinetics for $10 billion at $85 per share, reflecting strong confidence in Crinetics, with the deal expected to close in the third quarter of this year.
- Product Potential Analysis: Crinetics' Palsonify, after FDA approval, generated $10.7 million in its first full quarter, and as the only once-daily oral treatment, it has a strong market position that is expected to yield significant revenue for Vertex.
- Pipeline Prospects: Crinetics' atumelnant is in late Phase 3 trials targeting severe congenital adrenal hyperplasia, and if approved, it will address a significant unmet medical need, enhancing Vertex's product portfolio with substantial sales potential.
- Financial Strength Support: Vertex boasts over $5.5 billion in cash reserves and has secured a $4.5 billion bridge loan, ensuring that it can continue investing in new drug development post-acquisition, driving future growth and market competitiveness.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Overview: Vertex Pharmaceuticals is acquiring Crinetics for $10 billion, paying $85 per share in cash, reflecting strong confidence in Crinetics' future potential, with the deal expected to close in the third quarter of this year.
- Market Potential: Crinetics' Palsonify has received FDA approval and generated $10.7 million in revenue in its first full quarter post-launch, positioning it as the only once-daily oral treatment in the market, indicating strong commercial prospects.
- Pipeline Highlights: Crinetics' atumelnant is in late Phase 3 clinical trials targeting severe congenital adrenal hyperplasia, and if approved, it is expected to address significant unmet medical needs with multi-billion dollar sales potential.
- Strategic Investment Significance: Vertex's CEO noted that this acquisition will leverage the momentum of Palsonify and is excited about atumelnant's transformative potential in CAH treatment, potentially generating up to $5 billion in annual sales for Vertex.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Crinetics Hits Record High After Vertex's $10 Billion Acquisition
- Significant Acquisition Premium: Crinetics Pharmaceuticals' stock soared to $83.63 after Vertex agreed to acquire the company for approximately $10 billion, with an offer of $85 per share representing a 102% premium over Monday's closing price, marking Vertex's largest acquisition to date and boosting market confidence in Crinetics.
- Positive Market Reaction: Crinetics shares surged 98%, while Dominion Energy and BioCryst gained 0.8% and 8%, respectively, indicating investor preference for companies linked to major acquisition activity and AI infrastructure demand, driving these stocks to new 52-week highs.
- Optimistic Outlook for Dominion: Dominion Energy's stock climbed to $70.59, a three-year high, benefiting from its extensive pipeline of power projects in Northern Virginia and its proposed merger with NextEra Energy, highlighting its growing role in supplying electricity to AI data centers.
- BioCryst's Strategic Shift: BioCryst Pharmaceuticals reached a new 52-week high of $11.02 as it plans to close its Birmingham research center and partner with external firms to cut costs and achieve profitability, with RBC Capital raising its price target to $14, reflecting strong momentum in biotech stocks.
See More
Vertex Acquires Crinetics for $10 Billion
- Acquisition Scale: Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion, with the deal expected to close in Q3 2026, marking a significant step for Vertex into a new disease area.
- Asset Value of Crinetics: Crinetics brings the drug PALSONIFY, the first approved once-daily oral therapy for adults with acromegaly, which is expected to fill a market gap; combined with other drugs, Crinetics' assets have a peak sales potential exceeding $5 billion annually.
- Financing Structure Analysis: The acquisition will be financed through a mix of cash and debt, with Vertex planning to utilize $4.5 billion in bridge financing alongside its $13 billion in cash and marketable securities, ensuring the feasibility of the acquisition without over-leveraging.
- Strategic Significance and Future Outlook: Although Vertex expects the deal to contribute to non-GAAP operating income only by 2029, this acquisition aligns with its strategy targeting serious diseases, addressing the company's diversification needs and signaling growth potential in new areas.
See More
